Cryocompression Use by Multidisciplinary Teams May Help Gynecologic Cancer QOL

Video

Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.

It is “everyone’s job” in a multidisciplinary team to monitor and adjust chemotherapy doses in patients with gynecologic cancers to prevent the occurrence of adverse effects including peripheral neuropathy, according to Mary Katherine Montes de Oca, MD.

At The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about how cryocompression can be used within a multidisciplinary team that manages gynecologic cancers, including medical oncologists, gynecologic oncologists, advanced practice providers, and neurologists.

According to Montes de Oca, a neurologist specializing in neuropathy helped with carrying out a self-controlled trial evaluating the use cryocompression to prevent peripheral neuropathy induced by chemotherapy in patients with gynecologic cancers. Additionally, she stated that this intervention may prevent neuropathy completely, suggesting that those who prescribe and administer chemotherapy to patients may recommend cryocompression to help improve their quality of life.

Transcript:

We partnered with a neurologist to help us design this study, particularly somebody who specialized in neuropathy and how to diagnose neuropathy. But any time that we’re prescribing these treatments, a lot of places have a multidisciplinary team with medical oncologists, gynecologic oncologists, and [advanced practice practitioners].

It’s everyone’s job to both recognize when patients are developing neuropathy so that we can adequately change the chemotherapy dose to prevent adverse [effects]. However, this intervention can really help us to prevent their neuropathy in the first place. There are various [practitioners] who are prescribing the chemotherapy and can mention this intervention to the patients to really improve their quality of life.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Related Content